VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
SRRKScholar Rock Holding Corporation
$47.33$5.7B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

SRRK logoScholar Rock Holding Corporation(SRRK)Earnings, Financials & Key Ratios

SRRK•NASDAQ
Price updated Jun 19, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryNeuroscience and Psychiatry Therapies
AboutScholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Show more
  • Revenue$0
  • EBITDA-$383M-53.1%
  • Net Income-$378M-53.5%
  • EPS (Diluted)-3.29-33.2%
  • ROE-123.08%-48.4%

SRRK Key Insights

Scholar Rock Holding Corporation (SRRK) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

  • ✗Profits declining 34.3% over 5 years
  • ✗Weak Piotroski F-Score: 1/9
  • ✗Shares diluted 14.9% in last year
  • ✗Expensive at 22.1x book value
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when SRRK posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

SRRK Price & Volume

Scholar Rock Holding Corporation (SRRK) stock price & volume — 10-year historical chart

Loading chart...

SRRK Growth Metrics

Scholar Rock Holding Corporation (SRRK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-
TTM-

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-54.72%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-32.69%

Return on Capital

10 Years-55%
5 Years-63.93%
3 Years-75.83%
Last Year-99.03%

SRRK Recent Earnings

Scholar Rock Holding Corporation (SRRK) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 3/12 qtrs (25%)
Q2 2026Latest
May 7, 2026
Metric
Actual
Est
EPS
$0.83-1.2%
$0.82
Rev
—
$5M
Q2 2026
Mar 3, 2026
Metric
Actual
Est
EPS
$0.88+0.3%
$0.88
Rev
—
$2M
Q4 2025
Nov 14, 2025
Metric
Actual
Est
EPS
$0.90-7.8%
$0.84
Rev
—
$50,000
Q3 2025
Aug 6, 2025
Metric
Actual
Est
EPS
$0.98-48.5%
$0.66
Rev
—
$55,560
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 7, 2026
$0.83vs $0.82-1.2%
—vs $5M
Q2 2026Mar 3, 2026
$0.88vs $0.88+0.3%
—vs $2M
Q4 2025Nov 14, 2025
$0.90vs $0.84-7.8%
—vs $50,000
Q3 2025Aug 6, 2025
$0.98vs $0.66-48.5%
—vs $55,560
Based on last 12 quarters of dataView full earnings history →

SRRK Peer Comparison

Scholar Rock Holding Corporation (SRRK) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
KYMR logoKYMRKymera Therapeutics, Inc.Direct Competitor7.38B90.43-24.51-16.72%-6.12%-25.02%0.05
ARQT logoARQTArcutis Biotherapeutics, Inc.Direct Competitor3.28B26.21-201.6291.34%-0.57%-1.41%0.03
IMVT logoIMVTImmunovant, Inc.Direct Competitor7.26B35.34-12.76-68.16%0.00
ACVA logoACVAACV Auctions Inc.Direct Competitor1.13B6.48-16.6219.22%-7.97%-14.27%0.44
MDGL logoMDGLMadrigal Pharmaceuticals, Inc.Direct Competitor11.66B505.75-39.36432.05%-27.32%-50.15%0.59
PRTA logoPRTAProthena Corporation plcDirect Competitor467.51M8.93-1.97-92.84%-260.92%-49.88%0.05
BIIB logoBIIBBiogen Inc.Product Competitor29.02B196.5822.261.39%13.92%7.55%0.38
IONS logoIONSIonis Pharmaceuticals, Inc.Product Competitor12.25B74.12-31.1433.87%-30.87%-58.57%5.35

Compare SRRK vs Peers

Scholar Rock Holding Corporation (SRRK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs KYMR

Most directly comparable listed peer for SRRK.

Scale Benchmark

vs LLY

Larger-name benchmark to compare SRRK against a more recognizable public peer.

Peer Set

Compare Top 5

vs KYMR, ARQT, IMVT, ACVA

SRRK Income Statement

Scholar Rock Holding Corporation (SRRK) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
0020.49M15.4M18.82M33.19M0000
Revenue Growth %
-100%---24.83%22.16%76.41%-100%---
Cost of Goods Sold
669K807K54.22M74.06M108.47M123.04M2.84M1.94M0752K
COGS % of Revenue
--264.58%480.83%576.47%370.69%----
Gross Profit
-669K▲ 0%
-807K▼ 20.6%
-33.73M▼ 4079.1%
-58.66M▼ 73.9%
-89.65M▼ 52.8%
-89.85M▼ 0.2%
-2.84M▲ 96.8%
-1.94M▲ 31.9%
0▲ 100.0%
-752K▲ 0%
Gross Margin %
---164.58%-380.83%-476.47%-270.69%----
Gross Profit Growth %
94.47%-20.63%-4079.06%-73.93%-52.84%-0.22%96.83%31.89%100%-
Operating Expenses
25.03M50.69M20.82M28.22M40.27M44.52M168.45M250.12M384.64M409.15M
OpEx % of Revenue
--101.59%183.2%214.01%134.12%----
Selling, General & Admin
5.08M14.38M20.82M28.22M40.27M42.62M49.4M67.5M176.21M198M
SG&A % of Revenue
--101.59%183.2%214.01%128.4%----
Research & Development
19.94M36.31M54.22M74.06M108.47M124.44M119.06M182.61M208.44M211.16M
R&D % of Revenue
--264.58%480.83%576.47%374.91%----
Other Operating Expenses
-10K-56K-54.22M-74.06M-108.47M-122.54M0000
Operating Income
-25.03M▲ 0%
-50.69M▼ 102.5%
-54.54M▼ 7.6%
-86.88M▼ 59.3%
-129.92M▼ 49.5%
-134.37M▼ 3.4%
-171.29M▼ 27.5%
-252.05M▼ 47.1%
-384.64M▼ 52.6%
-409.57M▲ 0%
Operating Margin %
---266.16%-564.03%-690.48%-404.81%----
Operating Income Growth %
-54.4%-102.53%-7.59%-59.29%-49.54%-3.43%-27.48%-47.15%-52.6%-
EBITDA
-24.36M-49.88M-53.24M-85.39M-127.29M-131.38M-168.45M-250.12M-382.99M-407.97M
EBITDA Margin %
---259.8%-554.35%-676.52%-395.82%----
EBITDA Growth %
-55.8%-104.78%-6.72%-60.38%-49.08%-3.21%-28.21%-48.48%-53.12%-51.67%
D&A (Non-Cash Add-back)
669K807K1.3M1.49M2.63M2.99M2.84M1.94M1.66M1.6M
EBIT
-25.03M-50.69M-54.54M-86.88M-129.92M-132.47M-165.79M-239.46M-371.05M-400.16M
Net Interest Income
00000005.84M7.01M5.23M
Interest Income
01.42M0000012.68M13.9M12.61M
Interest Expense
00000006.84M6.89M7.38M
Other Income/Expense
34K1.37M3.54M395K-1.88M-132K5.51M5.76M6.71M845K
Pretax Income
-25M▲ 0%
-49.33M▼ 97.3%
-51M▼ 3.4%
-86.48M▼ 69.6%
-131.8M▼ 52.4%
-134.5M▼ 2.1%
-165.79M▼ 23.3%
-246.29M▼ 48.6%
-377.94M▼ 53.5%
-408.73M▲ 0%
Pretax Margin %
---248.88%-561.47%-700.46%-405.21%----
Income Tax
-44K000000000
Effective Tax Rate %
0.18%0%0%0%0%0%0%0%0%0%
Net Income
-25M▲ 0%
-49.33M▼ 97.3%
-51M▼ 3.4%
-86.48M▼ 69.6%
-131.8M▼ 52.4%
-134.5M▼ 2.1%
-165.79M▼ 23.3%
-246.29M▼ 48.6%
-377.94M▼ 53.5%
-408.73M▲ 0%
Net Margin %
---248.88%-561.47%-700.46%-405.21%----
Net Income Growth %
-54.22%-97.34%-3.39%-69.57%-52.4%-2.05%-23.26%-48.56%-53.45%-54.72%
Net Income (Continuing)
-25M-49.33M-51M-86.48M-131.8M-134.5M-165.79M-246.29M-377.94M-408.73M
Discontinued Operations
0000000000
Minority Interest
0000000000
EPS (Diluted)
-1.40▲ 0%
-3.15▼ 125.0%
-1.80▲ 42.9%
-2.77▼ 53.9%
-3.59▼ 29.6%
-2.21▲ 38.4%
-1.99▲ 10.0%
-2.47▼ 24.1%
-3.29▼ 33.2%
-3.21▲ 0%
EPS Growth %
-53.85%-125%42.86%-53.89%-29.6%38.44%9.95%-24.12%-33.2%-32.69%
EPS (Basic)
-1.40-3.15-1.80-2.77-3.59-2.21-1.99-2.47-3.29-
Diluted Shares Outstanding
17.91M15.66M27.54M30.73M36.71M59.61M75.98M99.84M114.7M127.28M
Basic Shares Outstanding
17.91M15.66M27.54M30.73M36.71M59.61M75.98M99.84M114.7M127.28M
Dividend Payout Ratio
----------

SRRK Balance Sheet

Scholar Rock Holding Corporation (SRRK) balance sheet — assets, liabilities & shareholders' equity

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
59.2M177.94M185.17M344.4M265.32M328.02M288.19M451.17M385.15M515.28M
Cash & Short-Term Investments
57.96M175.65M157.45M341.03M252.99M315.36M279.94M437.28M367.56M479.94M
Cash Only
56.46M115.07M36.31M160.36M212.84M103.28M101.86M177.88M323.53M430.54M
Short-Term Investments
1.5M60.58M121.14M180.67M40.16M212.09M178.08M259.4M44.04M49.4M
Accounts Receivable
0025M002.73M1.08M2.15M00
Days Sales Outstanding
--445.3--30.07----
Inventory
0000000000
Days Inventory Outstanding
----------
Other Current Assets
02.3M2.72M012.32M00017.58M35.34M
Total Non-Current Assets
2.44M3.4M11.21M43.9M39.13M30.14M22.84M23.76M19.13M19.97M
Property, Plant & Equipment
2.18M3.19M8.62M40.38M35.01M25.93M16.02M18.41M12.09M11.57M
Fixed Asset Turnover
--2.38x0.38x0.54x1.28x---0.00x
Goodwill
0000000000
Intangible Assets
0000004.07M2.4M00
Long-Term Investments
205K205K2.5M02.5M00003.81M
Other Non-Current Assets
50K098K3.52M1.62M4.22M2.75M2.96M7.04M8.4M
Total Assets
61.64M▲ 0%
181.34M▲ 194.2%
196.38M▲ 8.3%
388.31M▲ 97.7%
304.44M▼ 21.6%
358.17M▲ 17.6%
311.04M▼ 13.2%
474.92M▲ 52.7%
404.27M▼ 14.9%
535.25M▲ 0%
Asset Turnover
--0.10x0.04x0.06x0.09x---0.00x
Asset Growth %
88.02%194.2%8.3%97.73%-21.6%17.65%-13.16%52.69%-14.88%196.19%
Total Current Liabilities
5.02M31.12M32.81M42.56M64.3M36.39M32.74M46.94M55.42M59.64M
Accounts Payable
1.36M3.3M1.13M3.41M4.43M3.99M3.46M10.1M10.3M9.22M
Days Payables Outstanding
741.461.49K7.6116.814.9211.85444.71.9K-3.32K
Short-Term Debt
641K424K1.14M08.98M01.33M05.55M6.08M
Deferred Revenue (Current)
-641K20.21M20.92M18.82M33.19M00000
Other Current Liabilities
1.85M30K5.25M15K3.13M222K85K039.57M44.35M
Current Ratio
11.78x5.72x5.64x8.09x4.13x9.01x8.80x9.61x6.95x8.64x
Quick Ratio
11.78x5.72x5.64x8.09x4.13x9.01x8.80x9.61x6.95x8.64x
Cash Conversion Cycle
----------
Total Non-Current Liabilities
110.14M43.59M50.67M84.97M68.07M61.54M53.08M59.35M103.36M199.6M
Long-Term Debt
398K24K024.68M48.42M49.74M48.68M50.15M103.36M199.6M
Capital Lease Obligations
004.17M27.09M19.65M11.8M4.39M9.21M011.7M
Deferred Tax Liabilities
0-42.72M00000000
Other Non-Current Liabilities
109.74M871K9K5K000000
Total Liabilities
115.16M74.71M83.48M127.53M132.37M97.93M85.82M106.29M158.78M259.24M
Total Debt
1.04M462K5.3M57.14M84.47M69.4M61.82M65.13M108.92M205.67M
Net Debt
-55.42M-114.61M-31M-103.22M-128.37M-33.88M-40.04M-112.75M-214.61M-224.87M
Debt / Equity
-0.00x0.05x0.22x0.49x0.27x0.27x0.18x0.44x0.75x
Debt / EBITDA
----------0.50x
Net Debt / EBITDA
---------0.55x
Interest Coverage
--------35.02x-53.83x-54.25x
Total Equity
-53.52M▲ 0%
106.62M▲ 299.2%
112.9M▲ 5.9%
260.77M▲ 131.0%
172.07M▼ 34.0%
260.24M▲ 51.2%
225.22M▼ 13.5%
368.63M▲ 63.7%
245.49M▼ 33.4%
276.01M▲ 0%
Equity Growth %
-78.25%299.21%5.89%130.97%-34.01%51.23%-13.46%63.68%-33.41%238.91%
Book Value per Share
-2.996.814.108.484.694.372.963.692.142.17
Total Shareholders' Equity
-53.52M106.62M112.9M260.77M172.07M260.24M225.22M368.63M245.49M276.01M
Common Stock
4K26K30K34K35K52K76K94K108K119K
Retained Earnings
-57.52M-106.85M-157.85M-244.33M-376.13M-510.63M-676.42M-922.72M-1.3B-1.41B
Treasury Stock
5K000000000
Accumulated OCI
-2K-8K37K-2K-35K-884K92K160K94K690K
Minority Interest
0000000000

SRRK Cash Flow Statement

Scholar Rock Holding Corporation (SRRK) cash flow — operating, investing & free cash flow history

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
-21.74M24.57M-63.12M-60.27M-126.79M-132.69M-145.23M-200.95M-300.04M-303.46M
Operating CF Margin %
---308%-391.29%-673.84%-399.76%----
Operating CF Growth %
-43.56%213.04%-356.87%4.51%-110.36%-4.66%-9.44%-38.37%-49.31%-144.62%
Net Income
-25M-49.33M-51M-86.48M-131.8M-134.5M-165.79M-246.29M-377.94M-408.73M
Depreciation & Amortization
669K807K1.3M1.49M2.63M2.99M2.84M1.94M1.66M1.6M
Stock-Based Compensation
1.48M5.21M7.97M11.18M23.15M27.7M27.14M36.63M75.6M62.19M
Deferred Taxes
-199K272K176K0000000
Other Non-Cash Items
-162K-289K-401K2.3M7.67M5.51M1.19M186K1.7M21.19M
Working Capital Changes
1.47M67.9M-21.16M11.24M-28.44M-34.39M-10.61M6.59M-1.05M20.29M
Change in Receivables
00-25M25M000000
Change in Inventory
0000000000
Change in Payables
636K1.66M-1.34M2.1M1.02M-251K-529K6.63M208K4.78M
Cash from Investing
17.66M-60.23M-62.24M-63.5M134.31M-171.7M41.14M-76.06M218.69M178.8M
Capital Expenditures
-361K-1.49M-3.12M-4.09M-5.25M-1.06M-71K-98K-602K-399K
CapEx % of Revenue
--15.2%26.54%27.89%3.21%----
Acquisitions
0000000000
Investments
----------
Other Investing
18.03M-58.74M8K00013K000
Cash from Financing
50.5M94.27M48.88M247.82M44.95M194.83M102.57M353.03M228.4M418.02M
Debt Issued (Net)
-667K-667K-365K24.62M24.98M-975K0049.14M142.31M
Equity Issued (Net)
46.89M048.35M215.92M13.1M195.31M97.71M324.41M179.26M181.24M
Dividends Paid
0000000000
Share Repurchases
0000000000
Other Financing
4.28M94.94M900K7.28M6.87M492K4.87M28.61M094.47M
Net Change in Cash
46.43M▲ 0%
58.61M▲ 26.2%
-76.47M▼ 230.5%
124.05M▲ 262.2%
52.48M▼ 57.7%
-109.56M▼ 308.8%
-1.51M▲ 98.6%
76.02M▲ 5131.3%
147.05M▲ 93.4%
294.02M▲ 0%
Free Cash Flow
-22.1M▲ 0%
23.08M▲ 204.4%
-66.23M▼ 387.0%
-64.36M▲ 2.8%
-132.04M▼ 105.2%
-133.76M▼ 1.3%
-145.3M▼ 8.6%
-201.05M▼ 38.4%
-300.64M▼ 49.5%
-303.86M▲ 0%
FCF Margin %
---323.2%-417.83%-701.73%-402.97%----
FCF Growth %
-38.68%204.44%-386.97%2.83%-105.16%-1.3%-8.63%-38.37%-49.54%-32.01%
FCF per Share
-1.231.47-2.41-2.09-3.60-2.24-1.91-2.01-2.62-2.39
FCF Conversion (FCF/Net Income)
0.87x-0.50x1.24x0.70x0.96x0.99x0.88x0.82x0.79x0.74x
Interest Paid
0000000000
Taxes Paid
0000000000

SRRK Key Ratios

Scholar Rock Holding Corporation (SRRK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)
--185.78%-46.46%-46.29%-60.9%-62.22%-68.3%-82.95%-123.08%-163.52%
Return on Invested Capital (ROIC)
---110.69%-54.42%-96.83%-74.63%-62.43%-85.72%-201.2%-420.48%
Gross Margin
---164.58%-380.83%-476.47%-270.69%----
Net Margin
---248.88%-561.47%-700.46%-405.21%----
Debt / Equity
-0.00x0.05x0.22x0.49x0.27x0.27x0.18x0.44x0.75x
Interest Coverage
--------35.02x-53.83x-54.25x
FCF Conversion
0.87x-0.50x1.24x0.70x0.96x0.99x0.88x0.82x0.79x0.74x
Revenue Growth
-100%---24.83%22.16%76.41%-100%---
Related:SRRK Dividend History·SRRK Revenue History·SRRK Price History·SRRK P/E History·SRRK Financial Ratios·SRRK Institutional Holders

SRRK SEC Filings & Documents

Scholar Rock Holding Corporation (SRRK) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 7, 2026·SEC

Material company update

Mar 31, 2026·SEC

Material company update

Mar 3, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 3, 2026·SEC

FY 2025

Feb 27, 2025·SEC

FY 2024

Mar 19, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 7, 2026·SEC

FY 2025

Nov 14, 2025·SEC

FY 2025

Aug 6, 2025·SEC

SRRK Frequently Asked Questions

Scholar Rock Holding Corporation (SRRK) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Scholar Rock Holding Corporation (SRRK) grew revenue by 0.0% over the past year. Growth has been modest.

Scholar Rock Holding Corporation (SRRK) reported a net loss of $408.7M for fiscal year 2025.

Dividend & Returns

Scholar Rock Holding Corporation (SRRK) has a return on equity (ROE) of -123.1%. Negative ROE indicates the company is unprofitable.

Scholar Rock Holding Corporation (SRRK) had negative free cash flow of $303.9M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in SRRK back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →

How much would $100/month in SRRK be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →